Paper Details

  1. Home
  2. Paper Details

The use of diflunisal for transthyretin cardiac amyloidosis: a review.

Author: Barillas-LaraMaria Irene, BehroozLeili, FattouhMichael, IbrahimMichel, LacySpencer, MechanicOlivia, Saint CroixGarly Rushler

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

This systematic review examined the use of diflunisal in treating ATTR-CM, a heart condition caused by misfolded protein accumulation. Analyzing data from 6 studies involving 400 patients, the review found that diflunisal was associated with improvements in TTR concentration, left atrial volume, and cardiac troponin levels. Notably, diflunisal use was linked to lower mortality and fewer heart transplants, suggesting potential benefits for patients with ATTR-CM.
Paper Details　
Original Abstract of the Article :
Transthyretin cardiac amyloidosis (ATTR-CM) is caused by the accumulation of misfolded transthyretin (TTR) protein in the myocardium. Diflunisal, an agent that stabilizes TTR, has been used as an off-label therapeutic for ATTR-CM. Given limited data surrounding the use of diflunisal, a systematic re...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/s10741-021-10143-4

データ提供：米国国立医学図書館（NLM）

Diflunisal: A Potential Hope for Transthyretin Cardiac Amyloidosis

Transthyretin cardiac amyloidosis (ATTR-CM) is a rare but serious disease that can lead to heart failure and death. Researchers in the field of cardiology are working to develop new and effective treatments for ATTR-CM, aiming to improve patient outcomes and slow disease progression. This systematic review examines the use of diflunisal, a nonsteroidal anti-inflammatory drug, as an off-label treatment for ATTR-CM, exploring its potential benefits and risks.

Diflunisal's Potential as a Treatment for ATTR-CM

This systematic review suggests that diflunisal may have potential benefits for patients with ATTR-CM. The review found that diflunisal use was associated with improvements in several markers of disease severity, including TTR concentration, left atrial volume index, cardiac troponin I, and global longitudinal strain. The review also found that diflunisal use was associated with decreased mortality and reduced need for heart transplantation. These findings suggest that diflunisal may be a valuable treatment option for patients with ATTR-CM, offering potential for improving their health and prolonging their lives.

Implications for ATTR-CM Treatment

This systematic review's findings have important implications for ATTR-CM treatment, suggesting that diflunisal may be a promising therapeutic option for these patients. However, the review also highlights the need for further research, including randomized controlled trials, to confirm these findings and assess the long-term efficacy and safety of diflunisal in this population. While diflunisal shows promise for ATTR-CM treatment, ongoing research is essential to better understand its potential benefits and risks and guide clinicians in making informed treatment decisions.

Dr.Camel's Conclusion

This systematic review is like a camel traversing a challenging desert landscape, seeking a path towards better treatment options for those with ATTR-CM. The findings suggest that diflunisal may offer hope for improving patient outcomes and slowing disease progression, but further research is needed to solidify its role in the fight against this rare and debilitating disease.

Date :
  1. Date Completed 2022-04-29
  2. Date Revised 2022-05-31
Further Info :

Pubmed ID

34272629

DOI: Digital Object Identifier

10.1007/s10741-021-10143-4

Related Literature

Article Analysis
・Side Effects of diflunisal
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.